LY 2795050Alternative Names: 11C-LY2795050; LY2795050
Latest Information Update: 13 Feb 2015
At a glance
- Originator Eli Lilly
- Developer Eli Lilly; New York University School of Medicine; Yale University
- Class Imaging agents
- Mechanism of Action Opioid kappa receptor antagonists; Positron-emission tomography enhancers; Radiography enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Major depressive disorder; Post-traumatic stress disorders
Most Recent Events
- 01 Mar 2012 Clinical trials in Diagnostic imaging in USA (Parenteral)